Skip to main content
  • Saved

made a Post

STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world

STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world

Source :

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0238358

Background Mutations in STK11 (STK11m) and frequently co-occurring KRAS mutations (KRASm/STK11m) are associated with poor survival in metastatic NSCLC (mNSCLC) immuno-oncology trials. There are limited data regarding the prognostic significance of these mutations in a real-world setting.